Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma

NCT04000737 is registered in ClinicalTrials.gov with Yiviva Inc. as lead sponsor.

NCT NCT04000737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04000737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma
Lead sponsor
Yiviva Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 10, 2020
Completion date
November 19, 2024
Enrollment
62 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma